Clinical Trial Examining Effects of Monosodium Glutamate (MSG) on Irritable Bowel Syndrome (IBS) and Fibromyalgia (FM)

This study has been completed.
Sponsor:
Collaborator:
University of Arizona
Information provided by (Responsible Party):
Kathleen F. Holton, Oregon Health and Science University
ClinicalTrials.gov Identifier:
NCT00829218
First received: January 23, 2009
Last updated: December 21, 2013
Last verified: December 2013
  Purpose

Objective: Randomized, double blind, placebo-controlled, crossover, clinical trial to examine the effects of the food additive glutamate (in the form of MSG) on IBS and fibromyalgia.

Setting and Subjects: The Fibromyalgia Research Database at OHSU will be utilized to identify and recruit fibromyalgia patients who also have IBS to OHSU study centers.

Intervention: Approximately 60 male and female subjects aged 18-75 will be placed on a 1-month glutamate-free elimination diet. Those that respond positively to the diet (we are estimating 30-40 subjects), will then be randomized to receive either a citrus drink containing 5 grams of MSG; or placebo (the citrus drink alone)on three consecutive days one week apart.

The investigators are hypothesizing that those who react positively to the elimination diet will have symptom occurrence statistically more frequently when given the glutamate challenge, than when given placebo.


Condition Intervention
Irritable Bowel Syndrome
Fibromyalgia
Other: Glutamate additive-free diet
Other: Placebo diet

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Prevention
Official Title: A Clinical Trial Examining the Effects of the Food Additive Glutamate on Irritable Bowel Syndrome and Fibromyalgia

Resource links provided by NLM:


Further study details as provided by Oregon Health and Science University:

Primary Outcome Measures:
  • To evaluate the number of patients who have a positive response to a one month glutamate free diet, as measured by the Perception of Global Impression of Change (PGIC) scores [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
  • To assess whether symptoms return with MSG challenge statistically more frequently than with placebo as measured by symptom scores. [ Time Frame: 6 weeks, 7 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Improvement on Irritable Bowel Syndrome-Quality of Life (IBS-QOL) questionnaire [ Time Frame: 4 weeks, 7 weeks ] [ Designated as safety issue: No ]
  • Improvement in day-to-day functioning based on the Revised Fibromyalgia Impact Questionnaire [ Time Frame: 4 weeks, 7 weeks ] [ Designated as safety issue: No ]
  • A reduction in pain based on two visual analog scales, one for gut pain, and another for musculo-skeletal pain [ Time Frame: 4 weeks, 7 weeks ] [ Designated as safety issue: No ]

Enrollment: 60
Study Start Date: January 2009
Study Completion Date: May 2010
Primary Completion Date: November 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1 - Glutamate challenge
Glutamate challenge: After the one month glutamate free diet, subjects will receive 5 grams of glutamate for three days on one week and placebo for three days on the next week. Arm 1 is the 5 grams of glutamate which will be given in a mixed juice.
Other: Glutamate additive-free diet
All subjects will follow a diet for one month where all foods containing the additive glutamate have been removed. At the end of the one month diet, subjects who have responded positively to the diet will go onto the challenge arms of the study, where they will be randomized to receive placebo (mixed juice alone) for three days on one week, and 5 grams of glutamate in the mixed juice for three days on the other week.
Other Name: Glutamate will be used as a challenge in the form of MSG.
Placebo Comparator: 2- Placebo
Glutamate challenge: After the one month glutamate free diet, subjects will receive 5 grams of glutamate for three days on one week and placebo for three days on the next week. Arm 2 is the placebo arm, which will be juice with nothing added.
Other: Glutamate additive-free diet
All subjects will follow a diet for one month where all foods containing the additive glutamate have been removed. At the end of the one month diet, subjects who have responded positively to the diet will go onto the challenge arms of the study, where they will be randomized to receive placebo (mixed juice alone) for three days on one week, and 5 grams of glutamate in the mixed juice for three days on the other week.
Other Name: Glutamate will be used as a challenge in the form of MSG.
Other: Placebo diet
Juice with nothing added.

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Men and women aged 18-75 who fulfill criteria for Irritable Bowel Syndrome (IBS) and Fibromyalgia (FM)
  • They must live in the greater Portland, OR, metro area, have transportation to/from study site, have access to email
  • Willing to discontinue medications with bowel altering side effects

Exclusion Criteria:

  • Asthma
  • Inflammatory bowel disease
  • Colon cancer or active endometriosis
  • Any major abdominal surgery (excluding caesarean section, tubal ligation, hernia repair, gall bladder removal or appendectomy)
  • Female and pregnant
  • Currently taking pregabalin, gabapentin, or anti-psychotic medications and are unwilling/ unable to discontinue use
  • Suffered from alcohol/substance abuse or psychosis in the last two years.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00829218

Locations
United States, Oregon
Oregon Health & Science University
Portland, Oregon, United States, 97238
Sponsors and Collaborators
Oregon Health and Science University
University of Arizona
Investigators
Study Chair: Douglas Taren, PhD University of Arizona
Principal Investigator: Kathleen F Holton, MPH, PhDc University of Arizona and Oregon Health & Science Univ.
Study Director: Kimberly D Jones, PhD Oregon Health and Science University
  More Information

Publications:
Responsible Party: Kathleen F. Holton, Research Assistant Professor, Oregon Health and Science University
ClinicalTrials.gov Identifier: NCT00829218     History of Changes
Other Study ID Numbers: 4763
Study First Received: January 23, 2009
Last Updated: December 21, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by Oregon Health and Science University:
Irritable Bowel Syndrome
Fibromyalgia
Glutamate
Diet
Food additives

Additional relevant MeSH terms:
Irritable Bowel Syndrome
Fibromyalgia
Myofascial Pain Syndromes
Syndrome
Colonic Diseases, Functional
Colonic Diseases
Intestinal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Muscular Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Neuromuscular Diseases
Nervous System Diseases
Disease
Pathologic Processes

ClinicalTrials.gov processed this record on September 22, 2014